OncoMatch/Clinical Trials/NCT05654454
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Is NCT05654454 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Paclitaxel for non-small cell lung cancer.
Treatment: Bevacizumab · Paclitaxel · Carboplatin — BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR sensitizing mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Neutrophils ≥ 1.5 × 10^9/L; Platelets ≥ 100 × 10^9/L; Haemoglobin ≥ 90 g/L
Liver function
Bilirubin level ≤ 1.5 × ULN; AST and ALT < 3 × ULN (< 5 × ULN for patients with liver metastases); Alkaline phosphatase level < 3 × ULN (< 5 × ULN for patients with liver or bone metastases)
Neutrophils ≥ 1,5 × 10^9/L; Platelets ≥ 100 × 10^9/L; Haemoglobin ≥ 90 g/L; Bilirubin level ≤ 1.5 × ULN; AST and ALT < 3 × ULN (< 5 × ULN for patients with liver metastases); Alkaline phosphatase level < 3 × ULN (< 5 × ULN for patients with liver or bone metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05654454 currently recruiting?
Yes, this trial is currently recruiting patients.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages